drugset / Trial / NCT00066365
Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Inhaling aerosolized sargramostim before and after surgery may interfere with the growth of tumor cells and shrink the tumor so that it can be removed during surgery. Sargramostim may then kill any tumor cells remaining after surgery. This may be an effective treatment for osteosarcoma that has spread to the lung. PURPOSE: This phase II trial is studying how well inhaled sargramostim works in treating patients who are undergoing surgery for the first recurrence of osteosarcoma that has spread to the lung.
Timeline
- Start
- 2004-07
- Primary completion
- 2010-07
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sargramostim | Protein / enzyme biologic | 240 ug | Inhaled |
| Subject | sargramostim | Protein / enzyme biologic | 1000 ug | Inhaled |
| Subject | sargramostim | Protein / enzyme biologic | 1750 ug | Inhaled |